Compare Stocks: DRUG, OCUL, PBH, and BHC

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHC Bausch Health Cos	$5.70 +0.8%	$6.00	$4.33 ▼ $8.00	$2.13B	0.37	2.29 million shs	1.25 million shs
DRUG Bright Minds Biosciences	$51.80 -3.2%	$71.29	$48.94 ▼ $123.75	$504.13M	-5.36	81,327 shs	210,971 shs
OCUL Ocular Therapeutix	$9.65 -1.7%	$9.92	$6.23 ▼ $16.44	$2.12B	0.97	2.14 million shs	1.62 million shs
PBH Prestige Consumer Healthcare	$46.51 +1.9%	$50.31	$42.62 ▼ $71.07	$2.21B	0.33	565,986 shs	467,651 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHC Bausch Health Cos	0.00%	+0.71%	-9.66%	+19.02%	-14.43%
DRUG Bright Minds Biosciences	0.00%	-15.05%	-30.51%	-21.26%	+1.61%
OCUL Ocular Therapeutix	0.00%	-3.40%	-10.81%	-1.93%	-23.17%
PBH Prestige Consumer Healthcare	0.00%	+3.55%	-9.28%	-5.80%	-26.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHC Bausch Health Cos	$5.70 +0.8%	$6.00	$4.33 ▼ $8.00	$2.13B	0.37	2.29 million shs	1.25 million shs
DRUG Bright Minds Biosciences	$51.80 -3.2%	$71.29	$48.94 ▼ $123.75	$504.13M	-5.36	81,327 shs	210,971 shs
OCUL Ocular Therapeutix	$9.65 -1.7%	$9.92	$6.23 ▼ $16.44	$2.12B	0.97	2.14 million shs	1.62 million shs
PBH Prestige Consumer Healthcare	$46.51 +1.9%	$50.31	$42.62 ▼ $71.07	$2.21B	0.33	565,986 shs	467,651 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHC Bausch Health Cos	0.00%	+0.71%	-9.66%	+19.02%	-14.43%
DRUG Bright Minds Biosciences	0.00%	-15.05%	-30.51%	-21.26%	+1.61%
OCUL Ocular Therapeutix	0.00%	-3.40%	-10.81%	-1.93%	-23.17%
PBH Prestige Consumer Healthcare	0.00%	+3.55%	-9.28%	-5.80%	-26.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHC Bausch Health Cos	2.14	Hold	$8.00	40.47% Upside
DRUG Bright Minds Biosciences	2.78	Moderate Buy	$143.83	177.67% Upside
OCUL Ocular Therapeutix	2.77	Moderate Buy	$25.75	166.84% Upside
PBH Prestige Consumer Healthcare	2.00	Hold	$67.67	45.48% Upside

Current Analyst Ratings Breakdown

Latest DRUG, OCUL, PBH, and BHC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/22/2026	PBH Prestige Consumer Healthcare	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D+)
9/21/2026	BHC Bausch Health Cos	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
9/16/2026	OCUL Ocular Therapeutix	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$23.00
9/16/2026	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$25.00
9/15/2026	DRUG Bright Minds Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/20/2026	DRUG Bright Minds Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Market Perform
8/20/2026	DRUG Bright Minds Biosciences	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	BHC Bausch Health Cos	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/19/2026	DRUG Bright Minds Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$145.00
8/17/2026	DRUG Bright Minds Biosciences	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$147.00
8/12/2026	OCUL Ocular Therapeutix	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold

(Data available from 9/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHC Bausch Health Cos	$10.85B	0.20	$7.30 per share	0.78	$1.02 per share	5.58
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$8.33 per share	N/A
OCUL Ocular Therapeutix	$51.95M	40.80	N/A	N/A	$3.07 per share	3.14
PBH Prestige Consumer Healthcare	$1.09B	2.02	$5.20 per share	8.95	$39.89 per share	1.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHC Bausch Health Cos	$157M	-$2.96	N/A	1.42	N/A	-10.12%	-561.95%	6.31%	10/28/2026 (Estimated)
DRUG Bright Minds Biosciences	-$8.74M	-$2.08	N/A	N/A	N/A	N/A	-12.46%	-12.30%	N/A
OCUL Ocular Therapeutix	-$265.94M	-$1.42	N/A	N/A	N/A	-579.10%	-59.89%	-45.99%	11/3/2026 (Estimated)
PBH Prestige Consumer Healthcare	$190.30M	$3.57	13.03	9.14	1.46	15.57%	11.39%	5.66%	11/5/2026 (Estimated)

Latest DRUG, OCUL, PBH, and BHC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/17/2026	Q3 2026	DRUG Bright Minds Biosciences	-$1.2230	-$0.17	+$1.0530	-$0.17	N/A	N/A
8/6/2026	Q1 2027	PBH Prestige Consumer Healthcare	$0.8940	$0.98	+$0.0860	$0.61	$253.02 million	$265.71 million
8/3/2026	Q2 2026	OCUL Ocular Therapeutix	-$0.3955	-$0.35	+$0.0455	-$0.35	$13.20 million	$13.48 million
7/29/2026	Q2 2026	BHC Bausch Health Cos	$0.96	$1.26	+$0.30	$0.68	$2.59 billion	$2.83 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHC Bausch Health Cos	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
PBH Prestige Consumer Healthcare	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHC Bausch Health Cos	54.68	1.44	1.08
DRUG Bright Minds Biosciences	N/A	122.00	122.00
OCUL Ocular Therapeutix	0.14	13.10	13.03
PBH Prestige Consumer Healthcare	1.06	3.23	1.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHC Bausch Health Cos	78.65%
DRUG Bright Minds Biosciences	40.52%
OCUL Ocular Therapeutix	59.21%
PBH Prestige Consumer Healthcare	99.95%

Insider Ownership

Company	Insider Ownership
BHC Bausch Health Cos	20.67%
DRUG Bright Minds Biosciences	42.66%
OCUL Ocular Therapeutix	3.10%
PBH Prestige Consumer Healthcare	1.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHC Bausch Health Cos	20,300	374.14 million	296.81 million	Optionable
DRUG Bright Minds Biosciences	25	9.73 million	5.58 million	Not Optionable
OCUL Ocular Therapeutix	325	219.62 million	212.81 million	Optionable
PBH Prestige Consumer Healthcare	890	47.38 million	46.66 million	Optionable

DRUG, OCUL, PBH, and BHC Headlines

Recent News About These Companies

Prestige Consumer Healthcare Eyes Clear Eyes Recovery, $270M+ Free Cash Flow

2 hours ago | marketbeat.com

Critical Review: Aurora Cannabis (NASDAQ:ACB) and Prestige Consumer Healthcare (NYSE:PBH)

September 25 at 4:58 AM | americanbankingnews.com

555,894 Shares in Prestige Consumer Healthcare Inc. $PBH Purchased by Bank of America Corp DE

September 24 at 3:11 AM | marketbeat.com

Prestige Consumer Healthcare stock gains ahead of Sidoti event

September 22, 2026 | ad-hoc-news.deA

Prestige Consumer Healthcare stock falls as analysts stay cautious

September 20, 2026 | ad-hoc-news.deA

Prestige Consumer Healthcare Inc. (NYSE:PBH) Given Consensus Rating of "Hold" by Analysts

September 20, 2026 | americanbankingnews.com

Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives Consensus Recommendation of "Hold" from Brokerages

September 20, 2026 | marketbeat.com

Prestige Consumer Healthcare stock falls after sharp drop toward 52-week low

September 19, 2026 | ad-hoc-news.deA

PBH or NEOG: Which Is the Better Value Stock Right Now?

September 14, 2026 | zacks.com

Prestige Consumer Healthcare Inc. (PBH) Presents at Barclays 19th Annual Global Consumer Staples Conference Transcript

September 10, 2026 | seekingalpha.com

Prestige Consumer Healthcare Inc. to Participate in Barclays Global Consumer Conference

September 8, 2026 | globenewswire.com

Public Employees Retirement System of Ohio Takes $1.55 Million Position in Prestige Consumer Healthcare Inc. $PBH

September 8, 2026 | marketbeat.com

22,589 Shares in Prestige Consumer Healthcare Inc. $PBH Purchased by Jupiter Topco LLC

September 6, 2026 | marketbeat.com

Corient Private Wealth LP Invests $1.20 Million in Prestige Consumer Healthcare Inc. $PBH

September 5, 2026 | marketbeat.com

Legal & General Group Plc Purchases New Holdings in Prestige Consumer Healthcare Inc. $PBH

September 4, 2026 | marketbeat.com

Susquehanna International Group LLP Reduces Stake in Prestige Consumer Healthcare Inc. $PBH

September 2, 2026 | marketbeat.com

Football Stress May Be Following Fans to Bed, According to the Inaugural DenTek® Football Stress Test

September 1, 2026 | prnewswire.com

Bank of New York Mellon Corp Invests $15.38 Million in Prestige Consumer Healthcare Inc. $PBH

September 1, 2026 | marketbeat.com

Man Group plc Buys Shares of 119,056 Prestige Consumer Healthcare Inc. $PBH

August 30, 2026 | marketbeat.com

PBH vs. SYK: Which Stock Is the Better Value Option?

August 28, 2026 | zacks.com

North Star Asset Management Inc. Invests $9.83 Million in Prestige Consumer Healthcare Inc. $PBH

August 28, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

DRUG, OCUL, PBH, and BHC Company Descriptions

Bausch Health Cos NYSE:BHC

$5.70 +0.05 (+0.80%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$5.75 +0.06 (+0.98%)

As of 09/25/2026 07:56 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Bright Minds Biosciences NASDAQ:DRUG

$51.80 -1.71 (-3.20%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$51.86 +0.07 (+0.13%)

As of 09/25/2026 07:30 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Ocular Therapeutix NASDAQ:OCUL

$9.65 -0.17 (-1.73%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$9.65 0.00 (0.00%)

As of 09/25/2026 07:30 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Prestige Consumer Healthcare NYSE:PBH

$46.51 +0.86 (+1.89%)

Closing price 09/25/2026 03:59 PM Eastern

Extended Trading

$46.60 +0.09 (+0.20%)

As of 09/25/2026 07:30 PM Eastern

Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DRUG, OCUL, PBH, and BHC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DRUG, OCUL, PBH, and BHC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DRUG, OCUL, PBH, and BHC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DRUG, OCUL, PBH, and BHC Company Descriptions

Bausch Health Cos NYSE:BHC

Bright Minds Biosciences NASDAQ:DRUG

Ocular Therapeutix NASDAQ:OCUL

Prestige Consumer Healthcare NYSE:PBH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest DRUG, OCUL, PBH, and BHC Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest DRUG, OCUL, PBH, and BHC Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

DRUG, OCUL, PBH, and BHC Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

DRUG, OCUL, PBH, and BHC Company Descriptions

Bausch Health Cos NYSE:BHC

Bright Minds Biosciences NASDAQ:DRUG

Ocular Therapeutix NASDAQ:OCUL

Prestige Consumer Healthcare NYSE:PBH

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools